AP2015008731A0 - Pan-elr+ cxc chemokine antibodies - Google Patents

Pan-elr+ cxc chemokine antibodies

Info

Publication number
AP2015008731A0
AP2015008731A0 AP2015008731A AP2015008731A AP2015008731A0 AP 2015008731 A0 AP2015008731 A0 AP 2015008731A0 AP 2015008731 A AP2015008731 A AP 2015008731A AP 2015008731 A AP2015008731 A AP 2015008731A AP 2015008731 A0 AP2015008731 A0 AP 2015008731A0
Authority
AP
ARIPO
Prior art keywords
elr
pan
cxc chemokine
chemokine antibodies
antibodies
Prior art date
Application number
AP2015008731A
Other languages
English (en)
Inventor
Jeffrey Streetman Boyles
Derrick Ryan Witcher
Beth Ann Strifler
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AP2015008731A0 publication Critical patent/AP2015008731A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
AP2015008731A 2013-03-15 2014-03-05 Pan-elr+ cxc chemokine antibodies AP2015008731A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792800P 2013-03-15 2013-03-15
PCT/US2014/020605 WO2014149733A1 (fr) 2013-03-15 2014-03-05 Anticorps pan-elr+ cxc chimiokine

Publications (1)

Publication Number Publication Date
AP2015008731A0 true AP2015008731A0 (en) 2015-09-30

Family

ID=50343858

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008731A AP2015008731A0 (en) 2013-03-15 2014-03-05 Pan-elr+ cxc chemokine antibodies

Country Status (35)

Country Link
EP (4) EP4467566A3 (fr)
JP (1) JP6105146B2 (fr)
KR (1) KR101745230B1 (fr)
CN (2) CN105143259B (fr)
AP (1) AP2015008731A0 (fr)
AR (2) AR094960A1 (fr)
AU (1) AU2014237898B2 (fr)
CA (1) CA2901468C (fr)
CL (1) CL2015002531A1 (fr)
CY (1) CY1120459T1 (fr)
DK (1) DK2970447T3 (fr)
EA (1) EA029965B1 (fr)
ES (3) ES2769123T3 (fr)
HR (1) HRP20181047T1 (fr)
HU (1) HUE038834T2 (fr)
IL (2) IL241167B (fr)
JO (1) JO3580B1 (fr)
LT (1) LT2970447T (fr)
MA (1) MA38413A1 (fr)
ME (1) ME03094B (fr)
MX (1) MX364831B (fr)
MY (1) MY171213A (fr)
NZ (1) NZ711704A (fr)
PE (2) PE20191480A1 (fr)
PH (1) PH12015502090B1 (fr)
PL (1) PL2970447T3 (fr)
PT (1) PT2970447T (fr)
RS (1) RS57291B1 (fr)
SG (1) SG11201507686TA (fr)
SI (1) SI2970447T1 (fr)
TN (1) TN2015000377A1 (fr)
TR (1) TR201807613T4 (fr)
TW (1) TWI612059B (fr)
UA (1) UA116008C2 (fr)
WO (1) WO2014149733A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10047156B2 (en) * 2013-05-17 2018-08-14 Centre National De La Recherche Scientifique (Cnrs) Anti-CXCL1, CXCL7 and CXCL8 antibodies and their applications
US11485781B2 (en) 2017-08-17 2022-11-01 Massachusetts Institute Of Technology Multiple specificity binders of CXC chemokines
MX2020006171A (es) 2018-01-12 2020-09-03 Bristol Myers Squibb Co Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
KR102049180B1 (ko) * 2018-04-02 2019-11-26 고려대학교 산학협력단 체세포에서 유도 만능 줄기세포로의 역분화 유도용 조성물 및 이를 이용한 역분화 유도방법
TWI737000B (zh) 2018-10-22 2021-08-21 美商美國禮來大藥廠 用於治療化膿性汗腺炎之泛-ｅｌｒ＋ｃｘｃ趨化介素抗體
EP4045641A1 (fr) 2019-10-15 2022-08-24 Eli Lilly and Company Lignées cellulaires mammifères déficientes en lipase/estérase modifiées par recombinaison
CN113087795B (zh) * 2019-12-23 2025-06-10 上海普铭生物科技有限公司 针对趋化因子cx3cl1的抗体及其应用
CN115335406B (zh) * 2020-02-12 2026-01-30 伊莱利利公司 抗体或抗原-结合片段的结晶
TW202206457A (zh) * 2020-04-24 2022-02-16 美商美國禮來大藥廠 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體
CN112358547A (zh) * 2020-09-30 2021-02-12 浙江大学 抗人cxcl-2单克隆抗体3-d3及其编码基因和应用
WO2023192478A1 (fr) 2022-04-01 2023-10-05 Bristol-Myers Squibb Company Polythérapie avec des anticorps anti-il-8 et des anticorps anti-pd-1 pour le traitement du cancer
WO2026060205A1 (fr) 2024-09-13 2026-03-19 Eli Lilly And Company Anticorps anti-pan-elr+ cxc chimiokines et anticorps anti-il-23p19 pour le traitement de la rectocolite hémorragique

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040091503A1 (en) * 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
WO2007107003A1 (fr) * 2006-03-22 2007-09-27 Osteopharm Inc. Marqueurs de diagnostic, de suivi et de pronostic d'ostéoporose et d'évaluation du risque d'ostéoporose et de fractures ostéoporotiques
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
PE20090993A1 (es) * 2007-08-29 2009-07-08 Sanofi Aventis Anticuerpos anti-cxcr5 humanizados y derivados de los mismos
GB0806812D0 (en) * 2008-04-15 2008-05-14 Univ Leuven Kath Citrullinated cytokines
EA201071300A1 (ru) * 2008-05-14 2011-06-30 Эли Лилли Энд Компани Антитела к cxcr4
WO2011025962A1 (fr) * 2009-08-28 2011-03-03 Dan Allison Anticorps antikines se liant à plusieurs chimiokines cc
JP2011097867A (ja) * 2009-11-05 2011-05-19 Kurume Univ 脊柱靱帯骨化症のマーカーペプチド
JP2013518606A (ja) * 2010-02-09 2013-05-23 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規使用
EP2844290A4 (fr) * 2012-05-01 2015-12-16 Glaxosmithkline Llc Nouveaux anticorps

Also Published As

Publication number Publication date
EP4467566A2 (fr) 2024-11-27
EP3348569A1 (fr) 2018-07-18
IL241167A0 (en) 2015-11-30
CN109134652A (zh) 2019-01-04
JP2016512026A (ja) 2016-04-25
EP3608336B1 (fr) 2024-10-02
SG11201507686TA (en) 2015-10-29
CA2901468C (fr) 2018-02-20
IL241167B (en) 2019-10-31
MX364831B (es) 2019-05-08
PH12015502090B1 (en) 2020-07-08
MY171213A (en) 2019-10-02
PE20151531A1 (es) 2015-10-28
AU2014237898B2 (en) 2016-05-05
CN109134652B (zh) 2022-05-24
IL269387A (en) 2019-11-28
JP6105146B2 (ja) 2017-03-29
AR125831A2 (es) 2023-08-16
CN105143259B (zh) 2018-09-21
WO2014149733A1 (fr) 2014-09-25
HK1212714A1 (en) 2016-06-17
CY1120459T1 (el) 2019-07-10
MX2015013053A (es) 2016-05-18
IL269387B (en) 2021-05-31
PE20191480A1 (es) 2019-10-18
TR201807613T4 (tr) 2018-06-21
BR112015020174A2 (pt) 2017-08-29
AU2014237898A1 (en) 2015-08-20
EP2970447B1 (fr) 2018-05-16
EP4467566A3 (fr) 2025-04-23
KR20150119155A (ko) 2015-10-23
CL2015002531A1 (es) 2016-06-17
LT2970447T (lt) 2018-07-25
EP3348569B1 (fr) 2019-11-27
HRP20181047T1 (hr) 2018-08-24
CA2901468A1 (fr) 2014-09-25
EA201591514A1 (ru) 2016-03-31
ES2769123T3 (es) 2020-06-24
EP3608336A1 (fr) 2020-02-12
PT2970447T (pt) 2018-08-07
EP2970447A1 (fr) 2016-01-20
TWI612059B (zh) 2018-01-21
PL2970447T3 (pl) 2018-10-31
SI2970447T1 (en) 2018-06-29
RS57291B1 (sr) 2018-08-31
TW201520226A (zh) 2015-06-01
PH12015502090A1 (en) 2016-01-18
ES2675404T3 (es) 2018-07-11
KR101745230B1 (ko) 2017-06-08
DK2970447T3 (en) 2018-06-18
MA38413A1 (fr) 2017-10-31
CN105143259A (zh) 2015-12-09
ES2993153T3 (en) 2024-12-23
HUE038834T2 (hu) 2018-11-28
NZ711704A (en) 2019-12-20
TN2015000377A1 (en) 2017-01-03
EA029965B1 (ru) 2018-06-29
AU2014237898A8 (en) 2015-08-27
JO3580B1 (ar) 2020-07-05
UA116008C2 (uk) 2018-01-25
ME03094B (fr) 2019-01-20
AR094960A1 (es) 2015-09-09

Similar Documents

Publication Publication Date Title
ZA201808451B (en) Anti-fcrh5 antibodies
IL269387B (en) Antibodies against pan-elr cxc chemokines
SG11201509361TA (en) Novel antibodies
GB201322583D0 (en) Antibodies
IL243409A0 (en) Apocylated anti–fgfr2iiib antibodies
ZA201601437B (en) Antibodies
GB201308658D0 (en) Antibodies
GB201315486D0 (en) Antibodies
GB201300706D0 (en) Antibody
IL245488B (en) Anti- ccl17 antibodies
GB201312226D0 (en) Improved antibodies
GB201318283D0 (en) Antibodies
TH1501005445A (th) Pan-ELR+CXC CHEMOKINE แอนติบอดี้
AU5374P (en) Sungelodepi Angelonia angustifolia